Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.
Medscape

New-Onset Allergies Another Woe for Patients With Long COVID

Mounting evidence points to a link between new-onset allergies and Long COVID, with mast cell activation syndrome as a potential culprit.
Le Lézard

Gastroesophageal Reflux Disease Market in the US to Show Promising Growth at a CAGR of 6% During the Forecast Period (2025-2034) | DelveInsight

DelveInsight's Gastroesophageal Reflux Disease Market Insights report includes a comprehensive understanding of current treatment practices, gastroesophageal reflux disease emerging drugs, market ...

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-T) from The Globe and Mail including charting and trades.
BC Technology

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis ...
gut.bmj

Role of A2 beta casein in milk-induced eosinophilic oesophagitis: novel in-vivo and in-vitro findings

We read with interest the article by Santacroce about personalised medicine in eosinophilic oesophagitis (EoE) and the identification of novel therapeutic targets.1 While dietary approaches are ...